Daiwa Securities Group
NGNE icon

Daiwa Securities Group’s Neurogene NGNE Stock Holding History

Daiwa Securities Group’s Portfolio NGNE Stock Details NGNE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-3,227
Closed -$66K – 1350
2025
Q4 		$66K Buy
+3,227
New +$80.3K ﹤0.01% 1078
2022
Q4 		– Sell
-4
Closed – – 1355
2022
Q3 		$0 Hold
4
– – ﹤0.01% 1367
2022
Q2 		$0 Hold
4
– – ﹤0.01% 1400
2022
Q1 		$0 Hold
4
– – ﹤0.01% 1399
2021
Q4 		$0 Hold
4
– – ﹤0.01% 1426
2021
Q3 		$1K Hold
4
– – ﹤0.01% 1276
2021
Q2 		$1K Hold
4
– – ﹤0.01% 1202
2021
Q1 		$1K Hold
4
– – ﹤0.01% 1212
2020
Q4 		$1K Buy
+4
New +$977 ﹤0.01% 1191

Other funds holding NGNE

SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
TECP
Trails Edge Capital Partners Atlanta, Georgia $437M AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Daiwa Securities Group's NGNE Position: Q1 2026 in Review

Daiwa Securities Group sold out of Neurogene (NGNE) in Q1 2026, closing a stake of 3,227 shares — an estimated $66K sold.

Daiwa Securities Group first reported a position in NGNE in Q4 2020 and held it in 9 quarters. The position peaked at $66K in Q4 2025. 96 funds tracked by Wall St. Rank hold NGNE as of Q1 2026.

  • Daiwa Securities Group reported no remaining Neurogene position as of Q1 2026 after selling out during the quarter.
  • Daiwa Securities Group sold 3,227 Neurogene shares in Q1 2026, an estimated $66K.
  • Daiwa Securities Group first reported a position in Neurogene in Q4 2020 and held it in 9 quarters.
  • Daiwa Securities Group's Neurogene position peaked at $66K in Q4 2025.
  • 96 funds tracked by Wall St. Rank held Neurogene as of Q1 2026.

Based on Daiwa Securities Group's 13F filing for Q1 2026, filed 13 May 2026.